Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Return on Equity (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Return on Equity for 10 consecutive years, with 0.75% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity changed N/A to 0.75% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.75%, a N/A change, with the full-year FY2023 number at 0.91%, down 16.0% from a year prior.
  • Return on Equity was 0.75% for Q4 2025 at Crescent Biopharma, down from 0.1% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 2.18% in Q1 2025 to a low of 4.37% in Q3 2024.
  • A 5-year average of 0.81% and a median of 0.75% in 2025 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: plummeted -362bps in 2024, then surged 426bps in 2025.
  • Crescent Biopharma's Return on Equity stood at 0.71% in 2021, then crashed by -44bps to 1.03% in 2022, then rose by 15bps to 0.87% in 2023, then plummeted by -403bps to 4.37% in 2024, then skyrocketed by 83bps to 0.75% in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Return on Equity are 0.75% (Q4 2025), 0.1% (Q3 2025), and 0.43% (Q2 2025).